ACB $5.020 (-2.71%)

ACNNF $0.240 (-3.29%)

AERO $1.060 (-1.85%)

AGEEF $0.245 (-2%)

ALEAF $0.700 (-1.77%)

AMMJ $0.270 (-5.26%)

APHA $6.160 (1.82%)

ARNA $51.070 (-0.23%)

ATT:CNX $0.080 (0%)

ATTBF $0.020 (1.27%)

AUSA:CNX $0.740 (-1.33%)

AUSAF $0.567 (-0.77%)

AVXL $3.530 (6.65%)

BAMM:CNX $1.320 (-1.49%)

BBM:CNX $0.180 (-2.7%)

BBRRF $0.139 (6.59%)

BE:CNX $0.045 (-10%)

BIO:CNX $0.340 (-1.45%)

BLEVF $0.030 (-13.45%)

BLO:CNX $0.680 (0%)

BLOZF $0.516 (0.7%)

BUDZ $0.420 (2.46%)

BXNG $0.430 (0%)

CADMF $0.700 (4.01%)

CALI:CNX $0.120 (4.35%)

CANN $0.820 (-4.65%)

CARA $22.160 (-3.4%)

CBII:CNX $0.140 (7.69%)

CBIIF $0.112 (11.7%)

CBWTF $0.675 (2.09%)

CGC $25.560 (-2.96%)

CGRW $0.245 (6.52%)

CHOO:CNX $0.375 (0%)

CHOOF $0.285 (2.07%)

CNAB $0.425 (0.24%)

CNBX $0.255 (-1.92%)

CNGGF $1.150 (-1.71%)

CODI $19.060 (-0.73%)

CPMD $2.500 (0%)

CRBP $5.260 (-4.01%)

CRON $10.290 (0.59%)

CROP:CNX $0.070 (0%)

CRTPF $3.050 (-4.69%)

CRXPF $0.049 (-2%)

CSI:CNX $0.940 (5.62%)

CTST $1.310 (-4.38%)

CURR $3.900 (-1.27%)

CVSI $2.540 (-7.97%)

DIGP $0.120 (1.69%)

DXBRF $0.545 (8.46%)

EAPH $0.003 (0%)

EAT:CNX $0.145 (0%)

EEVVF $0.195 (-1.52%)

EMHTF $1.222 (1.66%)

EPWCF $0.053 (0%)

EVIO $0.395 (-2.98%)

FFRMF $0.039 (-8.37%)

FFT:CNX $0.055 (0%)

FNNZF $0.092 (0%)

FSDDF $0.077 (5.84%)

GGTTF $0.201 (-6.65%)

GLDFF $0.030 (-0.75%)

GLH:CNX $0.035 (0%)

GLNNF $0.032 (-5.81%)

GNBT $2.550 (-3.41%)

GRIN:CNX $0.205 (0%)

GRWG $4.950 (-2.75%)

GSTR:CNX $0.130 (4%)

GTBIF $10.210 (-4.11%)

GTII:CNX $13.580 (-3.62%)

GWPH $128.920 (-4.44%)

HEXO $4.360 (10.66%)

HHPHF $0.090 (-3.83%)

HLSPY $0.522 (-13.08%)

HMLSF $10.450 (-1.18%)

HMPPF $0.498 (0%)

HRVOF $0.352 (-5.88%)

HSTRF $0.244 (0%)

HUGE:CNX $0.095 (-5%)

IAN:CNX $2.810 (-2.77%)

IGC $1.140 (-2.56%)

IGXT $0.550 (-0.9%)

IIPR $95.210 (-2.19%)

IMLFF $0.228 (3.69%)

INQD $0.006 (3%)

IONC:CNX $0.065 (-7.14%)

IONKF $0.053 (-3.99%)

ISOL:CNX $0.290 (-3.33%)

ISOLF $0.217 (0.79%)

ITHUF $2.130 (-1.04%)

IVITF $0.184 (7.67%)

JWCAF $0.430 (2.77%)

KALTF $0.031 (4%)

KBEV:CNX $0.225 (0%)

KBEVF $0.172 (2.94%)

KHRNF $1.102 (2.04%)

KSHB $2.880 (-4%)

LHS:CNX $0.465 (-1.06%)

LHSIF $0.353 (0.23%)

LOVE:CNX $0.170 (0%)

LXLLF $0.344 (0%)

LXRP $0.651 (-8.27%)

LXX:CNX $0.890 (-5.32%)

MCIG $0.035 (-3.71%)

MDCL $3.900 (3.17%)

MEDIF $3.602 (-0.22%)

MGWFF $0.062 (0%)

MICWF $0.168 (1.82%)

MJ:CNX $0.230 (0%)

MJNA $0.037 (-2.8%)

MNTR $0.180 (8.96%)

MRRCF $0.128 (0.08%)

MWM:CNX $0.210 (-2.33%)

MYM:CNX $0.225 (-2.17%)

MYMMF $0.167 (-4.03%)

NCNNF $0.599 (-0.08%)

NDVAF $0.240 (0%)

NGW:CNX $0.225 (7.14%)

NRXCF $0.048 (0%)

NSPDF $0.069 (-1.71%)

NTEC $1.030 (7.12%)

NVTQF $0.144 (0%)

NWKRF $0.424 (0%)

NXGWF $0.162 (2.39%)

NXTTF $0.399 (-0.35%)

OH:CNX $7.100 (-3.66%)

ORHOF $5.380 (-3.1%)

OWCP $0.009 (0%)

PHGI:CNX $0.435 (-11.22%)

PHGRF $0.349 (-0.27%)

PHVAF $0.200 (-2.57%)

PILL:CNX $0.600 (0%)

PKG:CNX $0.125 (0%)

PLPRF $3.665 (0.14%)

PLUS:CNX $4.840 (-1.02%)

PMCB $0.039 (5.68%)

PNPL $0.300 (0%)

POTN $0.039 (0.26%)

PRCNF $0.085 (13.33%)

PTNYF $0.106 (5.81%)

QCA:CNX $0.155 (6.9%)

RDDTF $0.532 (-2.29%)

RLLVF $0.047 (30.19%)

RMHB $0.048 (-11.6%)

RQB:CNX $0.365 (-1.35%)

RQHTF $0.316 (-0.44%)

RVVQF $0.277 (-4.05%)

SLNG:CNX $0.740 (-10.84%)

SMG $100.200 (-0.44%)

SNN:CNX $1.490 (-1.97%)

SNNVF $1.105 (-3.11%)

SOL:CNX $1.060 (-10.92%)

SOLCF $0.834 (-7.87%)

SPLIF $0.107 (-7.04%)

SPRWF $1.030 (-0.96%)

SRNA $0.088 (-3.85%)

STEM:CNX $1.110 (-4.31%)

STMH $0.870 (-2.25%)

SUN:CNX $0.450 (-4.26%)

TBPMF $0.245 (-0.65%)

TCAN:CNX $0.800 (-11.11%)

TCNAF $0.709 (0%)

TER:CNX $6.010 (-1.96%)

TGEN $2.520 (-0.79%)

TGIF:CNX $0.335 (-5.63%)

TGIFF $0.249 (-7.83%)

THC:CNX $0.180 (-2.7%)

THCBF $0.132 (-2.17%)

TLRY $29.000 (-3.2%)

TOKI:CNX $0.055 (0%)

TRLFF $0.181 (5%)

TRPX $3.000 (1.52%)

TRSSF $4.536 (-1.83%)

TRTC $0.410 (4.51%)

TURV $0.255 (-5.29%)

VAPN:CNX $1.050 (-0.94%)

VBIO $0.120 (-40%)

VIDA:CNX $0.260 (-5.45%)

VIN:CNX $0.110 (0%)

VPRB $0.050 (16.28%)

VRNDF $0.585 (-2.11%)

VRT:CNX $0.245 (2.08%)

VRTHF $0.180 (0%)

VVCIF $0.297 (-2.9%)

WAYL:CNX $0.740 (0%)

WDDMF $1.020 (-3.77%)

WLDFF $0.347 (3.89%)

XXII $2.360 (4.89%)

ZDPY $0.300 (-6.13%)

ZYNE $8.260 (-2.25%)

Back

Greenstar Biosciences Announces Successful Testing Results Using Proprietary Grow Technology

Sep 11, 2019 • 11:12 AM GMT+0000
2 MIN READ  •  By Anthony Varrell
Share Share - Facebook Share - Twitter

GreenStar Biosciences Corp. (CSE: GSTR), a growth-oriented technology and services company that provides real estate, financial, management and other support to licensed cannabis businesses in the United States, is pleased to announce that it has received positive results from an initial cultivation test involving the growth of approximately 2,500 plants using the proprietary patent-pending grow and cultivation technology of Progressive Herbs Inc.. As previously announced, Capri PHGS LLC, a 50/50 joint venture between the Company and Progressive, holds the exclusive license to utilize Progressive’s proprietary cultivation technology. The Company also received results from independent laboratory testing on the three strains used in the initial cultivation test, which demonstrated total cannabinoid percentages between 22.85% to 32.54%, depending on the strain tested.

Seeds from three different proprietary (by agreement) strains were planted inside a 200-square-foot room at Cowlitz County Cannabis Cultivation Inc.’s warehouse facilities in Washington State. The results of this initial cultivation test appear to validate several efficiencies and advantages of the proprietary cultivation technology compared to traditional greenhouse operations:

1) High total cannabinoid levels:

  • Higher than normal total cannabinoid percentages of three strains tested (22.85%, 30.61% and 32.54% (compared to industry averages of between approximately 15-23% for similar strains).
  • No use of pesticides, herbicides or fungicides.
  • Free of heavy metals and contaminants.

2) Lower operational costs::

  • Room used for the initial cultivation test was readied for seed planting in two weeks, using “off-the-shelf” environmental control products.
  • Preliminary evidence that plants can be grown in a sub-optimal space with minimal, low-cost equipment.
  • Lower electricity costs (initial testing showed production of approximately 3 grams per watt used compared to industry average of 1-1.5 grams per watt).

3) Faster harvest time:

  • All plants were harvested in approximately 72 days, allowing for up to five harvest cycles per year (compared to an average of three to four per year for a traditional indoor grow operation).

Independent laboratory testing on random flower samples of the harvested plants was conducted by Praxis Laboratory (“Praxis“), an accredited Washington State testing facility. The results were as follows:

Strain Total THC Total CBD Total Cannabinoids
Strain 1 24.54% 2.24% 32.54%
Strain 2 9.78% 9.55% 22.85%
Strain 3 25.88% <0.01% 30.61%

 

Praxis also performed chemical residue screening for 59 different herbicides, pesticides and fungicides on Strain 2 during its grow cycle and reported a “pass” result for each chemical tested, with all but one showing a result of not-detected or below minimum detection limits. The testing confirms that the plants grown using the proprietary nutrient system contained no herbicides, pesticides or fungicides. In addition, a heavy metal detection analysis was performed by Medicine Creek Analytics, a Washington State accredited heavy metal screening lab, confirming no detected levels of arsenic, lead, cadmium or mercury in the flower samples provided. The Company believes these test results are very important given the numerous product recalls in both Canada and the United States due to pesticide, chemical, heavy metal and other contamination issues.

The Company, through Capri, intends to continue testing of this proprietary technology to confirm benefits and efficiencies on a larger scale. In addition, the Company, through Capri, intends to use the technology not only to secure low-cost indoor production for itself but also to build out a revenue stream through licensing of the proprietary technology to other producers.

“These successful initial test results provide preliminary evidence that we have a unique and effective technology that results in lower operating costs, more crop cycles per year and higher cannabinoid content than current industry norms. We believe we have proven the proof of concept effectiveness of this technology. We are excited to continue pursuing further testing and leveraging this proprietary technology. Not only did we see total cannabinoid content higher than industry norms, we also demonstrated the technology can generate cannabis flower at a lower cost per square foot of cultivation than current greenhouse technologies in use in the marketplace. In addition, the ability to grow cannabis without pesticides, herbicides and fungicides and absent of heavy metals and contaminants will put us at the forefront with regards to product quality and consumer confidence. Ultimately, further successful testing will generate a new revenue stream for the company.” states Rahim Rajwani, CEO of GreenStar.

About GreenStar

GreenStar is a growth-oriented technology and services company that provides real estate, financial, management, IP and branding support to licensed cannabis businesses. GreenStar also has exclusive licensing arrangements for proprietary technologies that support product development and operational efficiencies for its operations. Based in Vancouver, BC, GreenStar intends to facilitate growth through acquisitions and development of additional assets, products and technologies in legal cannabis markets by leveraging its capital markets, branding and operational expertise. GreenStar is committed to increasing shareholder value through aggressive expansion initiatives.

GreenStar’s assets include the property leases and intellectual property of Cowlitz County Cannabis Cultivation Inc. (“Cowlitz“), a Tier 2 licensed cannabis producer and processor located in Washington State. Cowlitz is a leading processor, marketer and vendor in the Washington State cannabis market. Known for sourcing high-quality cannabis sold at affordable prices, its products are sold to a broad and established consumer base. Cowlitz’s portfolio of branded products is available at approximately 20% of cannabis retailers throughout Washington State.

For further information please contact:

GreenStar Biosciences Corp.
Rahim Rajwani, CEO
info@greenstarbiosciences.com
Tel: (604) 834-9499

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY
OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts including, but not limited, to the statements about the advantages and efficiencies of the proprietary cultivation technology as compared to current greenhouse technologies and the ability to replicate these efficiencies and advantages on a larger scale or in subsequent testing, the ability to replicate the cannabinoid, chemical residue and heavy metal test results obtained in the initial cultivation test, the ability to license the proprietary cultivation technology to other producers, the ability to use the proprietary cultivation technology to secure low-cost indoor production, and the commercialization of the cultivation technology and the business plans of the Company using this technology. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including statements regarding the future plans and objectives of the Company are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are risks detailed from time to time in the filings made by the Company with securities regulations. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; and that the current Board and management may not be able to attain the Company’s corporate goals and objectives. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/47724

Source: Newsfile Corp. (September 11, 2019 – 7:03 AM EDT)

News by QuoteMedia
www.quotemedia.com

Share Share - Facebook Share - Twitter

Tags

Authored By

Anthony Varrell

Anthony Varrell is Managing Director of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Comments

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Technical420 newsletter.

 All good -- no spamming here.